Melanoma arises from neural crest-derived melanocytes which reside mostly in the skin in an adult organism. Epithelial-mesenchymal transition (EMT) is a tumorigenic programme through which cells acquire mesenchymal, more pro-oncogenic phenotype. The reversible phenotype switching is an event still not completely understood in melanoma. The EMT features and increased invasiveness are associated with lower levels of the pivotal lineage identity maintaining and melanoma-specific transcription factor MITF (microphthalmia-associated transcription factor), whereas increased proliferation is linked to higher MITF levels. However, the precise role of MITF in phenotype switching is still loosely characterized. To exclude the changes occurring upstream of MITF during MITF regulation in vivo, we employed a model whereby MITF expression was inducibly regulated by shRNA in melanoma cell lines. We found that the decrease in MITF caused only moderate attenuation of proliferation of the whole cell line population. Proliferation was decreased in five of 15 isolated clones, in three of them profoundly. Reduction in MITF levels alone did not generally produce EMT-like characteristics. The stem cell marker levels also did not change appreciably, only a sharp increase in SOX2 accompanied MITF down-regulation. Oppositely, the downstream differentiation markers and the MITF transcriptional targets melastatin and tyrosinase were profoundly decreased, as well as the downstream target livin. Surprisingly, after the MITF decline, invasiveness was not appreciably affected, independently of proliferation. The results suggest that low levels of MITF may still maintain relatively high proliferation and might reflect, rather than cause, the EMT-like changes occurring in melanoma.

Department of Transcription and Cell Signaling Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University Prague Czech Republic

See more in PubMed

Davies H, Bignell GR, Cox C, et al Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 2240–2251. PubMed

Wellbrock C, Rana S, Paterson H, et al Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One. 2008; 3: e2734. PubMed PMC

Obenauf AC, Zou Y, Ji AL, et al Therapy‐induced tumour secretomes promote resistance and tumour progression. Nature. 2015; 520: 368–72. PubMed PMC

Roesch A. Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene. 2015; 34: 2951–7. PubMed

Shannan B, Perego M, Somasundaram R, et al Heterogeneity in Melanoma. Cancer Treat Res. 2016; 167: 1–15. PubMed

Tulchinsky E, Pringle JH, Caramel J, et al Plasticity of melanoma and EMT‐TF reprogramming. Oncotarget. 2014; 5: 1–2. PubMed PMC

Roesch A, Paschen A, Landsberg J, et al Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. Eur J Cancer. 2016; 59: 109–12. PubMed

Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501: 328–37. PubMed PMC

Jolly MK, Boareto M, Huang B, et al Implications of the hybrid epithelial/Mesenchymal phenotype in metastasis. Front Oncol. 2015; 5: 155. PubMed PMC

Garraway LA, Widlund HR, Rubin MA, et al Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005; 436: 117–22. PubMed

McGill GG, Horstmann M, Widlund HR, et al Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell. 2002; 109: 707–18. PubMed

Dynek JN, Chan SM, Liu J, et al Microphthalmia‐associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res. 2008; 68: 3124–32. PubMed

Dar AA, Majid S, Bezrookove V, et al BPTF transduces MITF‐driven prosurvival signals in melanoma cells. Proc Natl Acad Sci USA. 2016; 113: 6254–8. PubMed PMC

Carreira S, Goodall J, Denat L, et al Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006; 20: 3426–39. PubMed PMC

Goodall J, Carreira S, Denat L, et al Brn‐2 represses microphthalmia‐associated transcription factor expression and marks a distinct subpopulation of microphthalmia‐associated transcription factor‐negative melanoma cells. Cancer Res. 2008; 68: 7788–94. PubMed

Cook AL, Sturm RA. POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis. Pigment Cell Melanoma Res. 2008; 21: 611–26. PubMed

Pinner S, Jordan P, Sharrock K, et al Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res. 2009; 69: 7969–77. PubMed PMC

Hoek KS, Goding CR. Cancer stem cells versus phenotype‐switching in melanoma. Pigment Cell Melanoma Res. 2010; 23: 746–59. PubMed

Thurber AE, Douglas G, Sturm EC, et al Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene. 2011; 30: 3036–48. PubMed PMC

Javelaud D, Alexaki VI, Pierrat MJ, et al GLI2 and M‐MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells. Pigment Cell Melanoma Res. 2011; 24: 932–43. PubMed

Roesch A, Fukunaga‐Kalabis M, Schmidt EC, et al A temporarily distinct subpopulation of slow‐cycling melanoma cells is required for continuous tumor growth. Cell. 2010; 141: 583–94. PubMed PMC

Sensi M, Catani M, Castellano G, et al Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol. 2011; 131: 2448–57. PubMed

Quintana E, Shackleton M, Sabel MS, et al Efficient tumour formation by single human melanoma cells. Nature. 2008; 456: 593–8. PubMed PMC

Quintana E, Shackleton M, Foster HR, et al Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 2010; 18: 510–23. PubMed PMC

Fang D, Nguyen TK, Leishear K, et al A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005; 65: 9328–37. PubMed

Parmiani G. Melanoma cancer stem cells: markers and functions. Cancers. 2016; 8: 34. PubMed PMC

Ondrusova L, Vachtenheim J, Reda J, et al MITF‐independent pro‐survival role of BRG1‐containing SWI/SNF complex in melanoma cells. PLoS One. 2013; 8: e54110. PubMed PMC

Wiederschain D, Wee S, Chen L, et al Single‐vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle. 2009; 8: 498–504. PubMed

Vachtenheim J, Ondrusova L, Borovansky J. SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia‐associated transcription factor in melanoma cells. Biochem Biophys Res Commun. 2010; 392: 454–9. PubMed

Hartman ML, Czyz M. Pro‐survival role of MITF in melanoma. J Invest Dermatol. 2015; 135: 352–8. PubMed

Caramel J, Papadogeorgakis E, Hill L, et al A switch in the expression of embryonic EMT‐inducers drives the development of malignant melanoma. Cancer Cell. 2013; 24: 466–80. PubMed

Vandamme N, Berx G. Melanoma cells revive an embryonic transcriptional network to dictate phenotypic heterogeneity. Front Oncol. 2014; 4: 352. PubMed PMC

Cheli Y, Giuliano S, Botton T, et al Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene. 2011; 30: 2307–18. PubMed

Santini R, Pietrobono S, Pandolfi S, et al SOX2 regulates self‐renewal and tumorigenicity of human melanoma‐initiating cells. Oncogene. 2014; 33: 4697–708. PubMed PMC

Vachtenheim J, Borovansky J. “Transcription physiology” of pigment formation in melanocytes: central role of MITF. Exp Dermatol. 2010; 19: 617–27. PubMed

Miller AJ, Du J, Rowan S, et al Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res. 2004; 64: 509–16. PubMed

Denecker G, Vandamme N, Akay O, et al Identification of a ZEB2‐MITF‐ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ. 2014; 21: 1250–61. PubMed PMC

Kim JE, Leung E, Baguley BC, et al Heterogeneity of expression of epithelial‐mesenchymal transition markers in melanocytes and melanoma cell lines. Front Genet. 2013; 4: 97. PubMed PMC

Shirley SH, Greene VR, Duncan LM, et al Slug expression during melanoma progression. Am J Pathol. 2012; 180: 2479–89. PubMed PMC

Arozarena I, Bischof H, Gilby D, et al In melanoma, beta‐catenin is a suppressor of invasion. Oncogene. 2011; 30: 4531–43. PubMed PMC

Wawrzyniak JA, Bianchi‐Smiraglia A, Bshara W, et al A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion. Cell Rep. 2013; 5: 493–507. PubMed PMC

Bianchi‐Smiraglia A, Bagati A, Fink EE, et al Microphthalmia‐associated transcription factor suppresses invasion by reducing intracellular GTP pools. Oncogene. 2017; 36: 84–96. PubMed PMC

Krauthammer M, Kong Y, Ha BH, et al Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012; 44: 1006–14. PubMed PMC

Falletta P, Sanchez‐Del‐Campo L, Chauhan J, et al Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes Dev. 2017; 31: 18–33. PubMed PMC

Vachtenheim J, Ondrusova L. Microphthalmia‐associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation. Exp Dermatol. 2015; 24: 481–4. PubMed

The Hedgehog/GLI signaling pathway activates transcription of Slug (Snail2) in melanoma cells

Widespread Expression of Hedgehog Pathway Components in a Large Panel of Human Tumor Cells and Inhibition of Tumor Growth by GANT61: Implications for Cancer Therapy